Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shawbrook to buy specialist lender ThinCats

(Sharecast News) - Shawbrook said on Tuesday that it has agreed to buy specialist lender ThinCats for an undisclosed sum. Shawbrook said the deal represents a strategic investment in accelerating the growth of its existing presence in the specialist SME lending market, "underlining the group's commitment to supporting UK SMEs with highly tailored finance facilities and relationship-led service".

It noted that ThinCats has an established market position, proven origination capabilities and a technology-enabled business model that is strategically aligned to Shawbrook's.

On completion, the ThinCats brand will operate as part of Shawbrook's portfolio of brands, "continuing to support owner-managed and sponsor-backed businesses with funding for event-driven needs".

The acquisition will include a projected loan book of around £0.7bn with corresponding risk-weighted assets of approximately £0.6bn.

Shawbrook said the deal is expected to be earnings per share accretive in the first full financial year post completion, delivering a "highly attractive" return on invested capital.

Shawbrook chief executive Marcelino Castrillo, said: "ThinCats is a leading UK FinTech with an excellent track record for delivering bespoke funding to growth-focused SMEs, whose owners, management teams and sponsors value speed, flexibility and certainty.

"ThinCats' approach is aligned to our own strategy of leveraging technology, credit excellence and an entrepreneurial culture to deliver a premium proposition to established UK SMEs.

"This acquisition will serve to further scale-up and deepen our presence in the very large and growing SME market. As part of the Shawbrook Group, the ThinCats proposition will benefit from our platform, including distribution channels, investment and funding structure, which will allow us to scale the brand more efficiently and serve even more UK SMEs with highly tailored funding solutions."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.